Merck Invests Up to $2 Billion for Rights to Chinese Heart Drug

Merck Invests Up to $2 Billion for Rights to Chinese Heart Drug
2 months ago

In a significant move within the pharmaceutical industry, Merck & Co. has announced plans to acquire the rights to a promising heart drug under development in China, with the total investment reaching up to $2 billion. This decision underscores Merck's commitment to expanding its portfolio in the cardiovascular market as part of a broader strategy to enhance its global footprint in the pharmaceutical landscape.

Continue reading
Bayer Secures EU Approval for Heart Drug, Mitigating Patent Worries

Bayer Secures EU Approval for Heart Drug, Mitigating Patent Worries
5 months ago

Bayer has recently received a significant endorsement from the European Union for its new heart medication, providing the company with much-needed momentum amidst ongoing concerns regarding patent expirations and market competition. This approval is seen as a pivotal moment for Bayer as it works to sustain its market position and boost its pharmaceutical division amidst an evolving landscape.

Continue reading